Precision BioSciences (NASDAQ:DTIL – Get Rating)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright also issued estimates for Precision BioSciences’ FY2026 earnings at $0.37 EPS.
Several other research analysts also recently commented on DTIL. BMO Capital Markets downgraded Precision BioSciences from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $7.00 to $4.00 in a research note on Monday. BTIG Research cut their target price on Precision BioSciences to $6.00 in a research note on Tuesday, November 15th.
Precision BioSciences Stock Down 1.2 %
Shares of NASDAQ DTIL opened at $0.89 on Wednesday. Precision BioSciences has a 52 week low of $0.86 and a 52 week high of $3.64. The business has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $1.29. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.37. The company has a market cap of $98.88 million, a P/E ratio of -0.63 and a beta of 1.45.
Institutional Trading of Precision BioSciences
About Precision BioSciences
Precision BioSciences, Inc is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases.
- Get a free copy of the StockNews.com research report on Precision BioSciences (DTIL)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.